Who are Capecitabine plus temozolomide VS Capecitabine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Liposomal doxorubicin hydrochloride, TS-1 and cisplatin, S-1 [Tegafur/Oteracil/gimeracil], Pemetrexed + Cisplatin /Carboplatin, cetuximab + cisplatin + vinorelbine, cytarabine and mitoxantrone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/capecitabine-plus-temozolomide-vs-capecitabine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Capecitabine plus temozolomide VS Capecitabine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Capecitabine plus temozolomide VS Capecitabine (Capecitabine plus temozolomide VS Capecitabine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antineoplastic agent. Area: Oncology.

phase 2 Antineoplastic agent Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Capecitabine plus temozolomide VS Capecitabine (Capecitabine plus temozolomide VS Capecitabine) — Asan Medical Center. Capecitabine is a prodrug that is converted into 5-fluorouracil, which interferes with DNA synthesis, thereby inhibiting cancer cell growth. Temozolomide works by methylating DNA, which triggers cell death in rapidly dividing cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Capecitabine plus temozolomide VS Capecitabine TARGET	Capecitabine plus temozolomide VS Capecitabine	Asan Medical Center	phase 2	Antineoplastic agent
Liposomal doxorubicin hydrochloride	Liposomal doxorubicin hydrochloride	Cephalon, Inc.	marketed	Antineoplastic agent	DNA and topoisomerase II
TS-1 and cisplatin	TS-1 and cisplatin	Taiho Pharmaceutical Co., Ltd.	phase 3	Antineoplastic agent	DNA
S-1 [Tegafur/Oteracil/gimeracil]	S-1 [Tegafur/Oteracil/gimeracil]	AstraZeneca	phase 3	Antineoplastic agent	Thymidylate synthase
Pemetrexed + Cisplatin /Carboplatin	Pemetrexed + Cisplatin /Carboplatin	Jiangsu Hansoh Pharmaceutical Co., Ltd.	phase 3	Antineoplastic agent	Thymidylate synthase, Dihydrofolate reductase, Glycinamide ribonucleotide formyltransferase
cetuximab + cisplatin + vinorelbine	cetuximab + cisplatin + vinorelbine	Merck KGaA, Darmstadt, Germany	phase 3	Antineoplastic agents	EGFR
cytarabine and mitoxantrone	cytarabine and mitoxantrone	Pfizer	phase 3	Antineoplastic agents

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antineoplastic agent class)

Acrotech Biopharma Inc. · 1 drug in this class
Asan Medical Center · 1 drug in this class
AstraZeneca · 1 drug in this class
Beijing Biostar Pharmaceuticals Co., Ltd. · 1 drug in this class
Cephalon, Inc. · 1 drug in this class
Jiangsu Hansoh Pharmaceutical Co., Ltd. · 1 drug in this class
Seattle Project Corporation · 1 drug in this class
Taiho Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Capecitabine plus temozolomide VS Capecitabine — Competitive Intelligence Brief. https://druglandscape.com/ci/capecitabine-plus-temozolomide-vs-capecitabine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab